

- [0101] 34. Madsen, J. M. 2001. Toxins as weapons of mass destruction. A comparison and contrast with biological-warfare and chemical-warfare agents. *Clin. Lab. Med.* 21:593-605.
- [0102] 35. Marrack, P., J. Kappler. 1990. The *staphylococcal* enterotoxins and their relatives. *Science.* 248: 705-709.
- [0103] 36. McCormick, J. K., J. M. Yarwood, and P. M. Schlievert. 2001. Toxic shock syndrome and bacterial superantigens: an update. *Ann Rev. Microbiol.* 55:77-104.
- [0104] 37. Mehrad, B., M. D. Burdick, and R. M. Strieter. 2009. Fibrocyte CXCR4 regulation as a therapeutic target in pulmonary fibrosis. *Int. J. Biochem. Cell Bio.* 41:1708-1718.
- [0105] 38. Meikle, L., K. Polliczai, A. Egnor, I. Kramvis, H. Lane, M. Sahin, and D. J. Kwiatkowski. 2008. Response of a Neuronal Model of Tuberous Sclerosis to Mammalian Target of Rapamycin (mTOR) Inhibitors: Effects on mTORC1 and Akt Signaling Lead to Improved Survival and Function. *J. Neurosci.* 28:5422-5432.
- [0106] 39. Miethke, T., C. Wahl, K. Heeg, B. Echtenacher, P. H. Krammer, and H. Wagner. 1992. T cell-mediated lethal shock triggered in mice by the superantigen SEB: critical role of TNF. *J. Exp. Med.* 175:91-98.
- [0107] 40. Mita, M. M., A. Mita, and E. K. Rowinsky. 2003. The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. *Cancer Biol. Ther.* 2:s169-77.
- [0108] 41. Mollick, J. A. M. Chintagumpala, R. G. Cook, and R. R. Rich. 1991. *Staphylococcal* exotoxin activation of T cells. Role of exotoxin-MHC class II binding affinity and class II isotype. *J. Immunol.* 146:463-468.
- [0109] 42. Mori, H., K. Inoki, K. Masutani, Y. Wakabayashi, K. Komai, R. Nakagawa, K. L. Guan, and A. Yoshimura. 2009. The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential. *Biochem. Biophys. Res. Comm.* 384:471-475.
- [0110] 43. Nagaki, M., Y. Muto, H. Ohnishi, S. Yasuda, K. Sano, T. Naito, T. Maeda, T. Yamada, and H. Moriwaki. 1994. Hepatic injury and lethal shock in galactosamine-sensitized mice induced by the superantigen *staphylococcal* enterotoxin B. *Gastroenterology.* 106: 450-458.
- [0111] 44. Proft, T., and J. D. Fraser. 2003. Bacterial superantigens. *Clin. Exp. Immunol.* 133:299-306.
- [0112] 45. Proft, T., S. Sriskandan, L. Yang, and J. D. Fraser. 2003. Superantigens and *Streptococcal* toxic shock syndrome. *Emerg. Infect. Dis.* 9:1211-1218.
- [0113] 46. Roy, C. J., K. L. Warfield, B. C. Welcher, R. F. Gonzales, T. Larsen, J. Hanson, C. S. David, T. Krakauer, and S. Bavari. 2005. Human leukocyte antigen-DQ8 transgenic mice: a model to examine the toxicity of aerosolized *staphylococcal* enterotoxin B. *Infect. Immun.* 73:2452-2460.
- [0114] 47. Saunders, R. N., M. S. Metcalfe, and M. L. Nicholson. 2001. Rapamycin in transplantation: a review of the evidence. *Kidney Int.* 59:3-16.
- [0115] 48. Sehgal, S. N. 2003. Sirolimus: its discovery, biological properties, and mechanism of action. *Transplant Proc.* 35:7S-14S.
- [0116] 49. Schlievert, P. M. 1993. Role of superantigens in human disease. *J. Infect. Dis.* 167:997-1002.
- [0117] 50. Scholl, P., A. Diez, W. Mourad, J. Parsonnet, R. S. Geha, and T. Chatila. 1989. Toxic shock syndrome toxin-1 binds to major histocompatibility complex class II molecules. *Proc. Natl. Acad. Sci. USA.* 86:4210-4214.
- [0118] 51. Smiley, S. T., M. Reers, C. Momottola-Hartshorn, M. Lin, A. Chen, T. W. Smith, G. D. Steele, and L. B. Chen. 1991. Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate forming lipophilic cation JC-1. *Proc. Natl. Acad. Sci. USA.* 88:3671-3675.
- [0119] 52. Stevens, D. L. 1996. The toxic shock syndromes. *Infect. Dis. Clin. North Am.* 10:727-746.
- [0120] 53. Stiles, B. G., S. Bavari, T. Krakauer, and R. G. Ulrich. 1993. Toxicity of *staphylococcal* enterotoxins potentiated by lipopolysaccharide: major histocompatibility complex class II molecule dependency and cytokine release. *Infect. Immun.* 61:5333-5338.
- [0121] 54. Strauss L., T. L. Whiteside, A. Knights, C. Bergmann, A. Knuth, A. Zippelius. 2007. Selective survival of naturally occurring human CD4+CD25+ Foxp3+ regulatory T cells cultured with rapamycin. *J. Immunol.* 178:320-329.
- [0122] 55. Takano, A., I. Usui, T. Haruta, J. Kawahara, T. Uno, M. Iwata, and M. Kobayashi. 2001. Mammalian target of rapamycin pathway regulates insulin signaling via subcellular redistribution of insulin receptor substrate 1 and integrates nutritional signals and metabolic signals of insulin. *Mol. Cell. Biol.* 21:5050-5062.
- [0123] 56. Thomson, A. W., H. R. Turnquist, and G. Raimondi. 2009. Immunoregulatory functions of mTOR inhibition. *Nature Rev. Immun.* 9:324-37.
- [0124] 57. Tremblay, F., A. Gagnon, A. Veilleux, A. Sorisky, and A. Marette. 2004. Activation of the mammalian target of rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3T3-L1 and human adipocytes. *Endocrinology.* 146:1328-37.
- [0125] 58. Visvanathan, K., A. Charles, J. Bannan, P. Pugach, K. Kashfi, and J. B. Zabriskie. 2001. Inhibition of bacterial superantigens by peptides and antibodies. *Infect. Immun.* 69:875-884.
- [0126] 59. Wienke, A., D. Roberts, and R. J. Gilbert. 1993. *Staphylococcal* food poisoning in the United Kingdom, 1969-1990. *Epidemiol. Infect.* 110:519-531.
- [0127] 60. Woltsman, A. M., S. W. van der Kooij, P. J. Coffer, R. Offringa, M. R. Daha, and C. van Kooten. 2003. Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27^{KIP1} expression. *Blood.* 101:1439-1445.
- [0128] 61. Wullschleger, S., R. Loewith, and M. N. Hall. 2006. TOR signaling in growth and metabolism. *Cell.* 124:471-484.
- [0129] 62. Yeung, R. S., J. M. Penninger, T. Kundig, W. Khoo, P. S. Ohashi, G. Kroemer, and T. W. Mak. 1996. Human CD4 and human major histocompatibility complex class II (DQ6) transgenic mice: supersensitivity to superantigen-induced septic shock. *Eur. J. Immunol.* 26:1074-1082.